Patent Application
20240043459
The present application relates to the fields of pharmaceutical chemistry, biochemistry, and medicine. In particular, it relates to crystalline forms of the compound of Formula I and methods of making and using the same.
The thyroid hormones (THs) play a critical role in growth, development, metabolism, and homeostasis. They are produced by the thyroid gland as thyroxine (T4) and 3,5,3′-triiodo-L-thyronine (T3). T4 is the major secreted form in humans and is enzymatically deiodinated by deiodinases to the more active form, T3, in peripheral tissues. THs exert their action by interacting with thyroid hormone receptors (TRs), which belong to the nuclear hormone receptor superfamily, and regulate the transcription of target genes.
TRs are expressed in most tissues and exist as two isoforms (TRα and TRβ). Tissue distribution studies, mouse knockout studies, and evaluation of patients with resistance to thyroid hormone (RTH) syndrome have established that TRα is the predominant isoform in the heart and regulates most cardiac functions, while the TRβ isoform predominates in the liver and the pituitary and regulates cholesterol metabolism and thyroid stimulating hormone (TSH) production, respectively. In addition, TRβ agonists may be used for the treatment of adrenoleukodystrophy (ALD) and lipid disorders such as hypercholesterolemia and fatty liver diseases, for example non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and glycogen storage disease (GSD). Some promising phosphonate TRβ agonists have been discovered; however, there exists a need for improved forms of such compounds to facilitate pharmaceutical development
Some embodiments provide a composition comprising a crystalline form of a compound of Formula I:
or a solvate thereof.
Other embodiments provide a process for making a crystalline form of a compound of Formula I, or a solvate thereof, comprising: dissolving an amorphous form of a compound of Formula I in a first solvent to create a first solution; adding a second solvent to the first solution to create a second mixture; and isolating a crystalline form of a compound of Formula I from the second mixture; wherein the compound of Formula I is:
Still other embodiments provide a process for making a crystalline form of a compound of Formula I, or a solvate thereof, comprising: dissolving a compound of Formula I in a first solvent to create a first solution; adding a seeding crystalline form of the compound of Formula I, or a solvate thereof, to the first solution to create a seeded mixture; and isolating a produced crystalline form of the compound of Formula I, or a solvate thereof, from the seeded mixture; wherein the compound of Formula I is:
Disclosed herein are crystalline forms of the compound of Formula (I), or solvates thereof, and methods of crystallizing the compound of Formula I. The compound of Formula I is show below:
Crystalline forms of Formula I, include tert-buty methyl ether (TBME) solvate crystalline form, toluene solvate crystalline form, ethanol solvate crystalline form, tetrahydrofuran (THF) solvate crystalline form, ethyl acetate (EtOAc) solvate crystalline form, acetone solvate crystalline form and crystalline Form C (described herein).
The present application relates to the first crystalline forms of the compounds of Formula I, as well as methods of crystallizing the various crystalline forms of the compounds of Formula I. The crystalline forms advantageously exhibit improved stability, processability and ease of manufacture. As a result, the crystalline forms of Formula I, particularly crystalline Form C, provide long-term stability and low adsorption and desorption of water vapor. Accordingly, the crystalline forms provide significant clinical improvements for the treatment of ALD and lipid disorders such as hypercholesterolemia and fatty liver diseases.
The present application also relates to various crystalline solvate forms and a nonsolvated form of the compound of Formula I, and methods of crystalizing the compound of Formula I.
Methods of Crystalizing the Compound of Formula I
Disclosed are methods of crystalizing the compound of Formula I, or a solvate thereof. Crystalline forms of the compound of Formula I may generally be obtained or produced by crystallizing the compound of Formula I under controlled conditions. In some embodiments, the method produces the TBME solvate crystalline form. In some embodiments, the method produces the toluene solvate crystalline form. In some embodiments, the method produces the ethanol solvate crystalline form. In some embodiments, the method produces the THF solvate crystalline form. In some embodiments, the method produces the EtOAc solvate crystalline form. In some embodiments, the method produces the acetone solvate crystalline form. In some embodiments, the method produces the crystalline Form C
In some embodiments, the method comprises dissolving an amorphous form of the compound of Formula I in a first solvent to create a first solution. In some embodiments, the method comprises dissolving a crystalline form of the compound of Formula I, or a solvate thereof, in a first solvent to create a first solution. In some embodiments, the method comprises dissolving a mixture of amorphous and crystalline forms of the compound of Formula I in a first solvent to create a first solution. In some embodiments, the method comprises adding a second solvent to the first solution to create a second mixture. In some embodiments, the second solvent is heptane.
In some embodiments, the method comprises seeding a crystalline form of the compound of Formula I, or a solvate thereof, in a first solution to create a seeded mixture. In some embodiments, the method comprises seeding the TBME solvate crystalline form in a first solution to create a seeded mixture. In some embodiments, the method comprises seeding toluene solvate crystalline form in a first solution to create a seeded mixture. In some embodiments, the method comprises seeding the ethanol solvate crystalline form in a first solution to create a seeded mixture. In some embodiments, the method comprises seeding the THF solvate crystalline form in a first solution to create a seeded mixture. In some embodiments, the method comprises seeding the EtOAc solvate crystalline form in a first solution to create a seeded mixture. In some embodiments, the method comprises seeding the acetone solvate crystalline form in a first solution to create a seeded mixture. In some embodiments, the method comprises seeding crystalline Form C in a first solution to create a seeded mixture.
In some embodiments, the method comprises seeding a crystalline form of the compound of Formula I, or a solvate thereof, in a second solution to create a seeded mixture. In some embodiments, the method comprises seeding the TBME solvate crystalline form in a second solution to create a seeded mixture. In some embodiments, the method comprises seeding toluene solvate crystalline form in a second solution to create a seeded mixture. In some embodiments, the method comprises seeding the ethanol solvate crystalline form in a second solution to create a seeded mixture. In some embodiments, the method comprises seeding the THF solvate crystalline form in a second solution to create a seeded mixture. In some embodiments, the method comprises seeding the EtOAc solvate crystalline form in a second solution to create a seeded mixture. In some embodiments, the method comprises seeding the acetone solvate crystalline form in a second solution to create a seeded mixture. In some embodiments, the method comprises seeding crystalline Form C in a second solution to create a seeded mixture.
In some embodiments, the seeded mixture produces a crystalline form of the compound of Formula I, or a solvate thereof. In some embodiments, the seeded mixture produces the TBME solvate crystalline form. In some embodiments, the seeded mixture produces the toluene solvate crystalline form. In some embodiments, the seeded mixture produces the ethanol solvate crystalline form. In some embodiments, the seeded mixture produces the THF solvate crystalline form. In some embodiments, the seeded mixture produces the EtOAc solvate crystalline form. In some embodiments, the seeded mixture produces the acetone solvate crystalline form.
In some embodiments, the seeded mixture produces crystalline Form C. In some embodiments, the seeded mixture seeded with the TBME solvate crystalline form produces crystalline Form C. In some embodiments, the seeded mixture seeded with the toluene solvate crystalline form produces crystalline Form C. In some embodiments, the seeded mixture seeded with the ethanol solvate crystalline form produces crystalline Form C. In some embodiments, the seeded mixture seeded with the THF solvate crystalline form produces crystalline Form C. In some embodiments, the seeded mixture seeded with the EtOAc solvate crystalline form produces crystalline Form C. In some embodiments, the seeded mixture seeded with the acetone solvate crystalline form produces crystalline Form C. In some embodiments, the seeded mixture seeded with crystalline Form C produces crystalline Form C.
In some embodiments, the method comprises isolating the crystalline form of the compound of Formula I, or a solvate thereof. In some embodiments, isolation is performed by filtration, such as hot-filtration. In some embodiments, the isolated product may be dried, such as by air drying.
In some embodiments, the first solvent may be a single solvent. In some embodiments, the first solvent may be a mixture of two or more solvents. In some embodiments, the first solvent may comprise EtOAc. In some embodiments, the first solvent may comprise ethanol. In some embodiments, the first solvent may comprise acetic acid. In some embodiments, the first solvent may comprise octanol. In some embodiments, the first solvent may comprise N-Methyl-2-pyrrolidone (NMP). In some embodiments, the first solvent may comprise TBME. In some embodiments, the first solvent may comprise toluene. In some embodiments, the first solvent may comprise pyridine. In some embodiments, the first solvent may comprise nitrobenzene. In some embodiments, the first solvent may comprise water. In some embodiments, the first solvent may comprise heptane. In some embodiments, the first solvent may comprise THF. In some embodiments, the first solvent may comprise acetone. In some embodiments, the first solvent may comprise acetonitrile.
In some embodiments, the second solvent may be a single solvent. In some embodiments, the second solvent may be a mixture of two or more solvents. In some embodiments, the second solvent may comprise EtOAc. In some embodiments, the second solvent may comprise ethanol. In some embodiments, the second solvent may comprise acetic acid. In some embodiments, the second solvent may comprise octanol. In some embodiments, the second solvent may comprise NMP. In some embodiments, the second solvent may comprise TBME. In some embodiments, the second solvent may comprise toluene. In some embodiments, the second solvent may comprise pyridine. In some embodiments, the second solvent may comprise nitrobenzene. In some embodiments, the second solvent may comprise water. In some embodiments, the second solvent may comprise heptane. In some embodiments, the second solvent may comprise THF. In some embodiments, the second solvent may comprise acetone. In some embodiments, the second solvent may comprise acetonitrile.
In some embodiments, the method further comprises agitation. In some embodiments, agitation is performed by stirring. In some embodiments, agitation is performed by sonication.
In some embodiments, portions of the method are performed at the same temperature. In some embodiments, portions of the method are performed at various temperatures. In some embodiments, portions of the method are performed at room temperature. In some embodiments, portions of the method are performed at 0° C. to 100° C. In some embodiments, portions of the method are performed at 20° C. to 25° C. In some embodiments, portions of the method are performed at 50° C. to 80° C. In some embodiments, portions of the method are performed at 50° C. to 60° C. In some embodiments, portions of the method are performed at 65° C. to 75° C. In some embodiments, portions of the method are performed at 23° C. In some embodiments, portions of the method are performed at 55° C. In some embodiments, portions of the method are performed at 70° C. In some embodiments, portions of the method may include the first solution, second mixture, seeded mixture, isolation of the crystalline form, and agitation.
Crystalline Forms of the Compound of Formula I
Also disclosed herein are crystalline forms of the compound of Formula I, or solvates thereof, and in particular the TBME solvate crystalline form, toluene solvate crystalline form, ethanol solvate crystalline form, THF solvate crystalline form, EtOAc solvate crystalline form, acetone solvate crystalline form and crystalline Form C (described below).
The precise conditions for forming the TBME solvate crystalline form may be empirically determined and it is only possible to give a number of methods which have been found to be suitable in practice.
The TBME solvate crystalline form was characterized using various techniques which are described in further detail in the experimental methods section.
The precise conditions for forming the toluene solvate crystalline form may be empirically determined and it is only possible to give a number of methods which have been found to be suitable in practice.
The toluene solvate crystalline form was characterized using various techniques which are described in further detail in the experimental methods section.
The precise conditions for forming the ethanol solvate crystalline form may be empirically determined and it is only possible to give a number of methods which have been found to be suitable in practice.
The ethanol solvate crystalline form was characterized using various techniques which are described in further detail in the experimental methods section.
The precise conditions for forming the THF solvate crystalline form may be empirically determined and it is only possible to give a number of methods which have been found to be suitable in practice.
The THF solvate crystalline form was characterized using various techniques which are described in further detail in the experimental methods section.
The precise conditions for forming the EtOAc solvate crystalline form may be empirically determined and it is only possible to give a number of methods which have been found to be suitable in practice.
The EtOAc solvate crystalline form was characterized using various techniques which are described in further detail in the experimental methods section.
The precise conditions for forming the acetone solvate crystalline form may be empirically determined and it is only possible to give a number of methods which have been found to be suitable in practice.
The acetone solvate crystalline form was characterized using various techniques which are described in further detail in the experimental methods section.
Some embodiments include an unsolvated crystalline form of Formula (I), referred to herein as crystalline Form C. The precise conditions for forming crystalline Form C may be empirically determined and it is only possible to give a number of methods which have been found to be suitable in practice.
Crystalline Form C was characterized using various techniques which are described in further detail in the experimental methods section.
As is well understood in the art, because of the experimental variability when X-ray diffraction patterns are measured on different instruments, the peak positions are assumed to be equal if the 2 θ values agree to within a certain degree of variability. For example, the United States Pharmacopeia states that if the angular setting of the 10 strongest diffraction peaks agree to within ±0.2° with that of a reference material, and the relative intensities of the peaks do not vary by more than 20%, the identity is confirmed. Accordingly, in some embodiments, peak positions recited herein include variability within ±0.5° 2 θ. In other embodiments, peak positions recited herein include variability within ±0.2° 2 θ. As disclosed herein, the term “approximately” when referring to values of 2 θ is defined as ±0.5° 2 θ.
Meanwhile,
Crystalline Form C can therefore be characterized as non-hygroscopic and stabile over a wide range of humidity. Crystal form C also shows good crystallinity, the content of residual solvents is very low (<0.1%), the melting point is relatively high (approx. 122° C.) and crystal form C does not show any evidence of hydrate formation. In contrast, the solvate forms tend to desolvate producing mixtures of the solvate and the amorphous form. Such advantageous and unexpected non-hygroscopicity and stability demonstrated by Crystalline Form C may be capitalized on. For example, methods of treatment and pharmaceutical compositions Crystalline Form C may provide long-term stability and low adsorption and desorption of water vapor, and may provide significant clinical improvements for the treatment of ALD and lipid disorders such as hypercholesterolemia and fatty liver diseases.
Methods of Treating Adrenoleukodystrophy (ALD) and Lipid Disorders
The compound of Formula I, and accordingly any of the compositions of the compound of Formula I disclosed herein, may be administered to a subject for treating or ameliorating ALD and lipid disorders such as hypercholesterolemia and fatty liver diseases, such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), or glycogen storage disease (GSD). The compound of Formula I can thus be administered to improve the condition of a subject, for example a subject suffering from ALD. As another example, the compounds of Formula I may be administered to treat lipid disorders such as hypercholesterolemia and fatty liver diseases.
The compound of Formula I may be administered in combination to a subject for treatment of ALD and lipid disorders. The compounds of Formula I may be administered to improve the condition of a patient suffering from hepatic encephalopathy. The compounds of Formula I may be administered to alleviate the symptoms associated with ALD. The compounds of Formula I may be administered to improve the condition of a patient suffering from hypercholesterolemia. The compounds of Formula I may be administered to alleviate the symptoms associated with hypercholesterolemia. The compounds of Formula I may be administered to improve the condition of a patient suffering from fatty liver diseases. The compounds of Formula I may be administered to alleviate the symptoms associated with fatty liver disease.
A therapeutically effective amount of the compounds of Formula I is administered to the subject. As will be readily apparent to one skilled in the art, the useful in vivo dosage to be administered and the particular mode of administration will vary depending upon the age, weight, the severity of the affliction, and mammalian species treated, the particular compounds employed, and the specific use for which these compounds are employed. (See e.g., Fingl et al. 1975, in “The Pharmacological Basis of Therapeutics”, which is hereby incorporated herein by reference in its entirety, with particular reference to Ch. 1, p. 1). The determination of effective dosage levels, that is the dosage levels necessary to achieve the desired result, can be accomplished by one skilled in the art using routine pharmacological methods. Typically, human clinical applications of products are commenced at lower do sage levels, with dosage level being increased until the desired effect is achieved. Alternatively, acceptable in vitro studies can be used to establish useful doses and routes of administration of the compositions identified by the present methods using established pharmacological methods.
A single daily dose may be administered. Alternatively, multiple doses, for example two, three, four or five doses may be administered. Such multiple doses may be administered over a period of one month or two weeks or one week. In some embodiments, a single dose or multiple doses such as two, three, four or five doses may be administered daily.
Compositions of the Compound of Formula I
Also disclosed herein are compositions of the compound of Formula I. The compositions of the present application advantageously are particularly suited for oral and/or intravenous administration to patients with ALD or lipid disorders. The compositions may, in some embodiments, be obtained by one of the processes disclosed in the present application. For example, the amorphous crystallization method and/or the seeding crystallization method may yield the compositions of the present application.
The compositions, in some embodiments, can include a crystalline form of the compound of Formula I (e.g., TBME solvate crystalline form, toluene solvate crystalline form, ethanol solvate crystalline form, THF solvate crystalline form, EtOAc solvate crystalline form, acetone solvate crystalline form, and/or Crystalline Form C disclosed herein). In some embodiments, the composition may include at least about 20% by weight of a crystalline form of the compound of Formula I. In some embodiments, the composition may include at least about 50% by weight of a crystalline form of the compound of Formula I. In some embodiments, the composition may include at least about 80% by weight of a crystalline form of the compound of Formula I. In some embodiments, the composition may include at least about 95% by weight of a crystalline form of the compound of Formula I. In some embodiments, the composition may include at least about 50% by weight of Crystalline Form C. In some embodiments, the composition may include at least about 80% by weight of Crystalline Form C. In some embodiments, the composition may include at least about 95% by weight of Crystalline Form C. In some embodiments, the composition may include at least about 99% by weight of Crystalline Form C. In some embodiments, the composition consists essentially of a crystalline form of the compound of Formula I. In some embodiments, the composition consists essentially of Crystalline Form C. In some embodiments, the composition includes a mixture of at least two (e.g., two, three or four forms) of the TBME solvate crystalline form, toluene solvate crystalline form, ethanol solvate crystalline form, THF solvate crystalline form, EtOAc solvate crystalline form, acetone solvate crystalline form, and Crystalline Form C.
The compositions, in some embodiments, include Crystalline Form C. For example, the compositions may include at least about 20%; at least about 50%; at least about 90%; at least about 95%; or at least about 99% of Crystalline Form C. Similarly, the compositions may also include, for example, the TBME solvate crystalline form, toluene solvate crystalline form, ethanol solvate crystalline form, THF solvate crystalline form, EtOAc solvate crystalline form or acetone solvate crystalline form. The compositions may optionally include at least about 20%; at least about 50%; at least about 90%; at least about 95%; or at least about 99% of the TBME solvate crystalline form, toluene solvate crystalline form, ethanol solvate crystalline form, THF solvate crystalline form, EtOAc solvate crystalline form, acetone solvate crystalline form, and/or Crystalline Form C.
Pharmaceutical Compositions
The compositions of the compound of Formula I of the present application may also be formulated for administration to a subject (e.g., a human). The compound of Formula I, and accordingly the compositions disclosed herein, may be formulated for administration with a pharmaceutically acceptable carrier or diluent. The compound of Formula I may thus be formulated as a medicament with a standard pharmaceutically acceptable carrier(s) and/or excipient(s) as is routine in the pharmaceutical art. The exact nature of the formulation will depend upon several factors including the desired route of administration. Typically, the compound of Formula I is formulated for oral, intravenous, intragastric, subcutaneous, intravascular or intraperitoneal administration.
The pharmaceutical carrier or diluent may be, for example, water or an isotonic solution, such as 5% dextrose in water or normal saline. Solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, sodium lauryl sulfate, and/or polyethylene glycols; binding agents, e.g. starches, gum arabic, gelatin, microcrystalline cellulose, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, lauryl sulfates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manners, for example, by means of mixing, granulating, tabletting, sugar-coating, or film-coating processes.
Liquid dispersions for oral administration may be syrups, emulsions or suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
Suspensions and emulsions may contain a carrier, for example a natural gum, agar, sodium alginate, pectin, microcrystalline cellulose, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular injections may contain, together with the compounds of Formula I, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol and sodium lauryl sulfate.
The medicament may consist essentially of the compound of Formula I and a pharmaceutically acceptable carrier.
Oral formulations may generally include dosages of the compound of Formula I in the range of about 1 mg to about 100 g. Accordingly, in some embodiments, the oral formulation includes the compound of Formula I compositions disclosed herein in the range of about 1 mg to about 50 g. In some embodiments, the oral formulation includes the compound of Formula I compositions disclosed herein in the range of about 1 mg to about 100 mg. In some embodiments, the oral formulation includes the compound of Formula I compositions disclosed herein in the range of about 1 mg to about 20 mg. In some embodiments, the oral formulation includes the compound of Formula I compositions disclosed herein in the range of about 5 mg to about 15 mg. In some embodiments, the oral formulation includes the compound of Formula I compositions disclosed herein at about 10 mg
Intravenous formulations may also generally include dosages of the compound of Formula I in the range of about 1 mg to about 100 g (for example, about 10 mg). In some embodiments, the intravenous formulation has a concentration of about 5 to about 300 mg/mL of the compound of Formula I (preferably about 25 to about 200 mg/mL, and more preferably about 40 to about 60 mg/mL).
The composition, or medicament containing said composition, may optionally be placed is sealed packaging. The sealed packaging may reduce or prevent moisture and/or ambient air from contacting the composition or medicament. In some embodiments, the packaging includes a hermetic seal. In some embodiments, the packaging sealed under vacuum or with an inert gas (e.g., argon) within the sealed package. Accordingly, the packaging can inhibit or reduce the rate of degradation for the composition or medicament stored within the packaging. Various types of sealed packaging are known in the art. For example, U.S. Pat. No. 5,560,490, is hereby incorporate by reference in its entirety, discloses an exemplary sealed package for medicaments.
Additional embodiments are disclosed in further detail in the following examples, which are not in any way intended to limit the scope of the claims.
XRPD analysis was carried out on a Bruker D8 advance or a Philips PW 1710. In embodiments using the Bruker D8 device, samples were scanned using CuKa radiation, tube power of 35 kV/45 mA, a VANTEC1 detector, a step size of 0.017° 2 θ, a time per step 105±5 sec time per step, and a scanning range of 2°-50° 2 θ. Samples were also prepared as received or slightly crushed. Silicon single crystal sample holders were used, with sample diameters of 12 mm and depths of 0.1 mm.
In embodiments using the Philips PW device, samples were scanned using Copper Kα radiation, a step size of 0.02° 2 θ, a 2.4 sec time per step, and a scanning range of 2°-50° 2 θ. 0.1 mm sample holders were used. Samples were measured without any special treatment other than the application of slight pressure to get a flat surface. Measurements were performed at an ambient air atmosphere.
Thermogravimetric measurements were carried out with a Perkin-Elmer Thermobalance TGS-2 (aluminum sample pans, N2 atmosphere 50 ml/min., heating rate 10 K/min, range 25 to 200 or 350° C.).
Thermogravimetric Fourier-Transform Infrared Spectroscopy measurements were carried out with a Netzsch Thermo-Microbalance TG 209 coupled to a Bruker FTIR Spectrometer Vector 22 (sample pans with a pinhole, N2 atmosphere, heating rate 10 K/min, range 25 to 250° C.).
Differential Scanning calorimetry Analysis (DSC)
In some embodiments, DSC was carried out with a Perkin Elmer DSC7 with the following experimental conditions: 3.26 to 4.51 mg sample mass, closed gold sample pan, temperature range −50° C. to 100° C./150° C./225° C., heating rate 10 or 20 K/min. The samples were weighed in air.
In other embodiments, DSC was carried out with a Perkin Elmer DSC7 with the following experimental conditions: 3.53 mg sample mass, closed gold sample pan, temperature range −50° C. to 150° C., heating rate 20 K/min. The sample was weighed in air.
The samples were dissolved in CDCl3. The NMR spectra were recorded on a Bruker spectrometer (Ultrashield TM, B ACS 60, 300 MHz).
Karl Fischer moisture analyses were carried out according to standard procedures.
The sample (9.869 mg) was placed on a Pt pan, and the sample was allowed to equilibrate at 25° C. at 50% relative humidity (r.h.) before starting a pre-defined humidity program. The predefined humidity programs include 1.0 hours 50%, from 50% r.h. to 0% r.h.; 5% r.h. per hour, 5 hours at 0% r.h., from 0% r.h. to 93% r.h.; 5% r.h. per hour, 5 hours at 93% r.h., from 93% r.h. to 50% r.h.; and 5% r.h. per hour, 1 hours at 50% r.h.
Fluka or Merck grade solvents were used. Fluka no. 95305 deionized water for relevant experiments.
In some embodiments, to determine the approximate solubility at room temperature, solvent was added in steps to the solid material. After every addition, the sample was well stirred. The addition of solvent was continued until complete dissolution or until 20 ml of solvent was added.
In other embodiments, aliquots of the test solvent were added to an accurately weighed amount of the compound of Formula I in small increments (usually 100-1000 μL), with sonication until complete dissolution was obtained, if possible. Dissolution was determined visually. The actual solubilities may be higher than reported due to slow dissolution rates or the use of excess solvent. The approximate solubility was determined in mg/mL to the nearest whole number.
Crystallization experiments were carried out with 40 mg to 256 mg of the compound. The solutions or slurries were stirred with a magnetic stirrer. The samples obtained after filtration (glass filter porosity P4) were air dried at ambient temperature and only for a short time to prevent possible desolvation of labile hydrates or solvates.
Starting material was obtained from Metabasis Therapeutics Inc. The material was characterized as amorphous as confirmed by XRPD,
The approximate solubility at ambient temperature must be known in order to carry out systematic crystallization experiments. The approximate solubility of the amorphous starting material A, at 23° C. are given in Table 1 below.
In the following Example, all evaporations and slurries gave oils. Slurrying the elevated temperature samples having tiny amounts of birefringent and extinctive solids in various solvents and antisolvents did not result in increased yield or size of the crystals. Stressing oils and the starting material under antisolvent vapor at elevated temperatures did result in tiny amounts of birefringent and extinctive solids embedded in oils and gels. Temperature cycling experiments showed no indication of crystallization. These results demonstrate the difficulty of crystallizing the compound of Formula I.
The details of various solution based crystallization experiments and results are given in Table 2 below.
The elevated temperature and humidity stress experiments resulted in oils containing small amounts of solids exhibiting birefringence and extinction. Sonication does not appear to offer any advantages over more common techniques. These results further confirm the difficulty of crystallizing the compound of Formula I. Heteroseeding using the diisopropyl ester analogue was also ineffective.
The details of various non-solvent based crystallization experiments and results are given in Table 3 below.
Spontaneous crystallization of the compound of Formula (I) was observed when the amorphous form was dissolved at room temperature in a mixture of THF and heptane (ratio 75:25 v/v). Additional heptane was added until a turbid “solution” was obtained. This turbid “solution” was stirred with a magnetic stirrer at room temperature for 16 hours, yielding a white paste. The XRPD measurement confirmed crystalline material,
The first attempt to desolvate the THF solvate at 80° C. in heptane (Test 15) resulted in a viscous sticky mass. After cooling to room temperature, the slurry was seeded with the ethanol solvate and stirred for 20 hours at room temperature. After filtration and air-drying at room temperature the sample contained only a very small amount of residual solvent and XRPD confirmed the production of a new crystal form (i.e., crystal form C),
Various crystallization experiments produced larger scale amounts of crystalline or solvate forms of the compound of Formula I. For example, the THF solvate (Test Result 20) and the unsolvated crystal form C (Test Results 21 and 23) were produced at a 200 mg scale.
The details of various crystallization experiments and results are given in Table 4 below.
The crystalline solid forms were characterized by XRPD, TGA, DSC and selected samples by solution NMR.
The XRPD results of the unsolvated crystal form C,
The characterization of the solvates by DSC,
The results of the TG mass loss and DSC Peak Temperatures of Example 4 are given in Table 5 below.
Phase equilibration experiments in solvent mixtures at different temperatures and seeding experiments were used to search for other unsolvated crystal forms of the compound of Formula I. A number of typical crystallization techniques (e.g., recrystallization from the melt or crystallization by cooling solutions) were not applicable because under these conditions nucleation of the compound is hindered. In turn desolvation of the solvates tends to produce the amorphous form.
Seeding concentrated solutions of the amorphous form in ethanol and THF using the unsolvated crystal form C at room temperature produced the ethanol solvate (Test Result 26) and the THF solvate (Test Result 29), respectively. The characterization of different solvates by DSC provided an overview of the stability of the solvates as estimated by the peak temperatures measured in hermetically closed sample pans.
Crystal form C was directly produced under the conditions in Test 30: The amorphous form was dissolved in EtOAc and heated to 75° C. Heptane was added slowly until a ratio of 1:7 v/v EtOAc/heptane was reached. The system was seeded with crystal form C and stirred for an additional time at 77° C. The solid was isolated by hot filtration of the suspension. XRPD showed that unsolvated crystal form C was produced,
For the crystallization of the unsolvated crystal form C, a solvent/antisolvent mixture which did not produce the corresponding solvate or an oil but still showed an acceptable solubility is desirable. In EtOAc/heptane mixtures at ratios below 1:7 v/v at 76° C. an oil was produced, even when seeding with crystal form C (Test Result 34).
The unsolvated crystal form C shows a high physical and chemical stability in EtOAc/heptane 1:7 v/v. Phase equilibration experiments for 3 days at room temperature and at 78° C. showed no transformation of the crystal form C from Test 37. Solution NMR showed the same spectrum as for the starting material (not shown).
Stirring a slurry of the amorphous form with seeds of crystal form C in EtOAc/heptane 1:7 v/v at room temperature for 18 hours also produced crystal form C (Test 42). However, at 2° C. the EtOAc solvate was formed (Test 43). The stability regions of the EtOAc solvate in solvent/antisolvent mixtures at different temperatures need to be tested. Crystal form C seems physically more stabile over a broader range of solvent/antisolvent ratios when using the EtOAc/heptane process than when using the ethanol/heptane process (Tests 33 and 34).
For a few samples the peak around 18° 2 θ in XRPD was broader, as seen in Test 44 and Test 45,
The details of the additional seeding crystallization experiments and results of the solid state of the samples of Example 5 are given in Table 6 below.
Desolvation of the solvates tends to produce the amorphous form. Storing the THF solvate at 96% r.h. at room temperature for 8 weeks (Test 48) produced a mixture of the solvate and the amorphous form, as confirmed by XRPD,
The results of the THF solvate stability test of Example 6 are given in Table 7 below.
Crystal form C does not show any evidence of hydrate formation. DVS analysis at 25° C. showed a very low adsorption/desorption of water vapor when humidity was increased from 50 to 93% r.h. or reduced from 50% r.h. to 0% r.h. (approx. ±0.1%). After storing for 3 days at 96% r.h. at room temperature (Test 49),
The results of the hydrate formation test of Example 7 are given in Table 8 below.
XRPD measurements of crystalline Form C of compound of Formula I were measured. Observed peaks are shown in
The range of data collected may be instrument dependent. Under most circumstances, peaks within the range of up to about 30° 2 θ were selected. Rounding algorithms were used to round each peak to the nearest 0.01° 2 θ, based on the instrument used to collect the data and/or the inherent peak resolution. The location of the peaks along the x-axis (° 2 θ) in both the figures and the tables were determined using proprietary software and rounded to one or two significant figures after the decimal point based upon the above criteria. Peak position variabilities are given to within ±0.2° 2 θ. For d-space listings, the wavelength used to calculate d-spacings was 1.5405929 Å, the Cu-Kα1 wavelength.
Table 10 provides XRPD data identified as “Prominent Peaks”. Prominent peaks are a subset of the entire observed peak list. Prominent peaks are selected from observed peaks by identifying preferably non-overlapping, low-angle peaks, with strong intensity.
Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet or PCT Request as filed with the present application are hereby incorporated by reference under 37 CFR 1.57, and Rules 4.18 and 20.6. The present application is a continuation of U.S. patent application Ser. No. 16/982,022, filed Sep. 17, 2020, which claims priority to PCT Application No. PCT/US2019/022824, filed Mar. 18, 2019, which claims priority to U.S. Provisional Application No. 62/646,540, filed Mar. 22, 2018, each of which are hereby incorporated by reference in their entirety.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16982022 | Sep 2020 | US |
| Child | 18486487 | US |
